Immune Mechanisms of Pulmonary Fibrosis with Bleomycin

Ishida, Yuko; Kuninaka, Yumi; Mukaida, Naofumi; Kondo, Toshikazu

doi:10.3390/ijms24043149

Cited by 50 publications

(15 citation statements)

References 312 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bleomycin is an antitumor agent that can be used to treat low‐grade gliomas. It can damage the DNA of tumor cells, thereby inhibiting their division and growth 87,88 . Vinblastine is an intravenously administered antineoplastic agent that can be used to treat low‐grade gliomas.…”

Section: Advances In Chemotherapy For Gliomamentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives

Liu,

Yang,

et al. 2024

CNS Neurosci Ther

View full text Add to dashboard Cite

Gliomas are the most common primary tumors of the central nervous system, with glioblastoma multiforme (GBM) having the highest incidence, and their therapeutic efficacy depends primarily on the extent of surgical resection and the efficacy of postoperative chemotherapy. The role of the intracranial blood–brain barrier and the occurrence of the drug‐resistant gene O6‐methylguanine‐DNA methyltransferase have greatly limited the efficacy of chemotherapeutic agents in patients with GBM and made it difficult to achieve the expected clinical response. In recent years, the rapid development of nanotechnology has brought new hope for the treatment of tumors. Nanoparticles (NPs) have shown great potential in tumor therapy due to their unique properties such as light, heat, electromagnetic effects, and passive targeting. Furthermore, NPs can effectively load chemotherapeutic drugs, significantly reduce the side effects of chemotherapeutic drugs, and improve chemotherapeutic efficacy, showing great potential in the chemotherapy of glioma. In this article, we reviewed the mechanisms of glioma drug resistance, the physicochemical properties of NPs, and recent advances in NPs in glioma chemotherapy resistance. We aimed to provide new perspectives on the clinical treatment of glioma.

show abstract

Section: Advances In Chemotherapy For Gliomamentioning

confidence: 99%

“…It can damage the DNA of tumor cells, thereby inhibiting their division and growth. 87 , 88 Vinblastine is an intravenously administered antineoplastic agent that can be used to treat low‐grade gliomas. It inhibits the mitogenic process of tumor cells and suppresses tumor cell growth.…”

Section: Advances In Chemotherapy For Gliomamentioning

confidence: 99%

Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives

Liu,

Yang,

et al. 2024

CNS Neurosci Ther

View full text Add to dashboard Cite

show abstract

“…Apart from bleomycin- and carbon tetrachloride-induced fibrosis models, radiation-induced organ fibrosis is also primary driven by myofibroblasts [ 34 , 35 ]. Myofibroblast activation is promoted by ionizing radiation through the activation of various signals such as TGF-β and Wnt/β-catenin [ 36 ].…”

Section: Mechanisms Of Radiation-induced Fibrosismentioning

confidence: 99%

Tissue fibrosis induced by radiotherapy: current understanding of the molecular mechanisms, diagnosis and therapeutic advances

Yu,

Xu,

Song

et al. 2023

J Transl Med

View full text Add to dashboard Cite

Cancer remains the leading cause of death around the world. In cancer treatment, over 50% of cancer patients receive radiotherapy alone or in multimodal combinations with other therapies. One of the adverse consequences after radiation exposure is the occurrence of radiation-induced tissue fibrosis (RIF), which is characterized by the abnormal activation of myofibroblasts and the excessive accumulation of extracellular matrix. This phenotype can manifest in multiple organs, such as lung, skin, liver and kidney. In-depth studies on the mechanisms of radiation-induced fibrosis have shown that a variety of extracellular signals such as immune cells and abnormal release of cytokines, and intracellular signals such as cGAS/STING, oxidative stress response, metabolic reprogramming and proteasome pathway activation are involved in the activation of myofibroblasts. Tissue fibrosis is extremely harmful to patients' health and requires early diagnosis. In addition to traditional serum markers, histologic and imaging tests, the diagnostic potential of nuclear medicine techniques is emerging. Anti-inflammatory and antioxidant therapies are the traditional treatments for radiation-induced fibrosis. Recently, some promising therapeutic strategies have emerged, such as stem cell therapy and targeted therapies. However, incomplete knowledge of the mechanisms hinders the treatment of this disease. Here, we also highlight the potential mechanistic, diagnostic and therapeutic directions of radiation-induced fibrosis.

show abstract

“…Additionally, there are transgenic models in which specific gene mutations associated with ILD, such as a mutant surfactant protein C gene (SFTPC) in alveolar type II (AT2) cells [ 16 ], are triggered to induce the development of pulmonary fibrosis. In addition, the bleomycin-induced pulmonary fibrosis model is widely used and well characterised [ 17 ]. This model has proven valuable in the exploration of novel pathogenic mechanisms that may have relevance to human disease.…”

Section: Introductionmentioning

confidence: 99%

The evolution ofin vitromodels of lung fibrosis: promising prospects for drug discovery

Kolanko,

Cargnoni,

Papait

et al. 2024

Eur Respir Rev

View full text Add to dashboard Cite

Lung fibrosis is a complex process, with unknown underlying mechanisms, involving various triggers, diseases and stimuli. Different cell types (epithelial cells, endothelial cells, fibroblasts and macrophages) interact dynamically through multiple signalling pathways, including biochemical/molecular and mechanical signals, such as stiffness, affecting cell function and differentiation. Idiopathic pulmonary fibrosis (IPF) is the most common fibrosing interstitial lung disease (fILD), characterised by a notably high mortality. Unfortunately, effective treatments for advanced fILD, and especially IPF and non-IPF progressive fibrosing phenotype ILD, are still lacking. The development of pharmacological therapies faces challenges due to limited knowledge of fibrosis pathogenesis and the absence of pre-clinical models accurately representing the complex features of the disease. To address these challenges, new model systems have been developed to enhance the translatability of preclinical drug testing and bridge the gap to human clinical trials. The use of two- and three-dimensionalin vitrocultures derived from healthy or diseased individuals allows for a better understanding of the underlying mechanisms responsible for lung fibrosis. Additionally, microfluidics systems, which replicate the respiratory system's physiologyex vivo, offer promising opportunities for the development of effective therapies, especially for IPF.

show abstract

Immune Mechanisms of Pulmonary Fibrosis with Bleomycin

Cited by 50 publications

References 312 publications

Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives

Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives

Tissue fibrosis induced by radiotherapy: current understanding of the molecular mechanisms, diagnosis and therapeutic advances

The evolution ofin vitromodels of lung fibrosis: promising prospects for drug discovery

Contact Info

Product

Resources

About